Back to Top

Information For Authors

Instructions for Authors

The primary focus of Applied In Vitro Toxicology is on the alternative testing methods and their applications of new cell- and tissue-based methods for predicting adverse effects in the pharmaceutical, veterinary, horticultural, chemical, and personal care industries. 


Manuscripts containing experiments done solely in animals or in which tissues used in vitro were obtained from animals in not consistent with the primary focus of the journal.  However, the use of animal data to confirm or validate a new in vitro approach would be appropriate.  Applied In Vitro Toxicology promotes the application of in vitro science to understand adverse events.


All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication, elsewhere except in the form of an abstract. Prior abstract publications should be described in the form of a footnote to the manuscript title. Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal. By submitting a manuscript to the Journal, the author(s) agree(s) to these conditions.  Certain exceptions from this rule apply (ex: some government employees, or work presented on behalf of governmental agencies).

Letters to the Editor(s):  

Letters to the Editor(s) are welcomed, but with a 500 word limit and no more than one (1) table OR figure, and with a maximum of four (4) references. 


All submitted manuscripts will be processed through plagiarism detection software. Plagiarized manuscripts will be rejected immediately.

Manuscripts should be submitted to


Please read all the instructions to authors before submitting.


Use of English Language

All submissions must be in English. Appropriate use of the English language is a requirement for review and publication in Applied In Vitro Toxicology.  For authors whose native language is not English, we suggest using a service that can aid in the translation and rewriting of material into correct and proper English usage.  The Publisher offers this service with a subsidy from the author prior to official submission (contact .   It is important to note that employing the use of the Publisher’s service does not guarantee acceptance of any paper.  All submissions are subject to peer review.


All submissions to the Journal are subject to peer review.  Authors are encouraged, but not required, to supply the names and email addresses of three to four individuals who are considered qualified to review the submitted material, as well as the names of individuals whom the authors would prefer not be selected as a reviewer. However, the review selection is ultimately at the discretion of the Editor.


Keywords (Areas of Expertise)

To facilitate the peer review process, select 4-6 keywords from the drop-down list of pre-selected terms when submitting your manuscript.   These keywords will assist in the selection of skilled reviewers in the field for the purposes of peer review.



All authors, including the co-authors, should be responsible for a significant part of the manuscript. All authors and co-authors should have taken part in writing the manuscript, reviewing it, and revising its intellectual and technical content. Any author whose name appears on a paper assumes responsibility and accountability for the results.

It is incumbent upon the submitting author to ensure the accuracy and inclusion of all contributing authors’ names and affiliations upon original submission of the paper.  Once a paper is accepted for publication, changes in authorship are NOT permitted. Changes in authorship after publication are strictly prohibited.

Working Groups or Committees as Authors

Working Groups and/or Committees should NOT be listed as an author.  Instead, the name of the Working Group and/or Committee and all of the participants, should be listed in the Acknowledgments section of the manuscript.

Corresponding Authorship

It is the Journal’s policy that only ONE corresponding author is listed on a paper. This designation should be determined at the time of submission. Additions to corresponding authors are not permitted after acceptance or in page proofs.


All submissions to Applied In Vitro Toxicology are subject to peer review. Upon submission of a manuscript, the authors are encouraged to suggest suitable referees, but must provide accurate email addresses for all such individuals.


Word Limits


Article Type

Maximum Word Limit*

Abstract Word Limit










Invited Review


















Case Study






Letters to the Editor

Max: 500



1 OR


*These limits relate to the text of the manuscript; word limits do NOT include the abstract, figure and/or table legends, acknowledgments, disclosures, or references.

  • All text submissions must be provided in Word. Do not submit PDFs of the manuscript or any text files. Submissions containing PDFs of text files will be returned without review.
  • All manuscript pages should be double spaced.
  • Include a title page that contains:

— The full title of the manuscript
— All contributing authors’ full names
— All contributing author’s complete affiliations
— A short title of no more than 50 characters, including spaces
— At least 4 (four) keywords [maximum of 8 (eight)]

Manuscript keywords (search terms): On the title page of the manuscript, include a minimum of three (3), maximum of six (6), search terms that will aid in the discoverability of the article in indexing services and search engines.  These terms may or may not be different from the terms you selected for the peer review process and areas of expertise.  You will be asked to retype these search terms in the submission form when uploading your manuscript.  These keywords will be included in the published article.  If the search terms entered do not match the manuscript, the manuscript will serve as the default.

  • Supply a structured abstract as the second page of text in the manuscript text file.  Structured abstracts should include these headings:  Introduction, Materials and Methods, Results, Discussion, and Conclusion(s).

After the abstract, the text should be constructed as follows:

  • Text: Organize the text as follows: Introduction; Materials and Methods; Results; Discussion; Conclusions; Acknowledgments; Disclosure; and References. At the first usage of a term, spell out the term and then provide the abbreviation or acronym in parentheses. Thereafter, use the abbreviation/acronym alone.
  • Acknowledgments: The author should acknowledge only those people and institutions that have made significant contributions to the study.
  • Disclosure Statement: Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. If no conflicts exist, the authors must state “No competing financial interests exist.”
  • Correspondence address: After the references, provide the name, address, and e-mail of the person to whom all correspondence should be directed. This information will be included at the end of the references in the final published version of the article.
  • NOTE:  If supplied, Supplemental Information will not be copyedited or typeset; they will be posted online-only as they were supplied.

Double space all references. Number each reference consecutively in the manuscript in order of citation. Number references consecutively (not alphabetically) in the reference section. Abbreviations of journal titles should follow MEDLINE.  List the names of the first three authors, followed by et al. Accuracy of citation is the responsibility of the authors; remember that inaccurate references are highly frustrating to the reader, the cited author, and indexing services.


Reference Examples:

Journal citation:

Mortin PJ, Sparks AB, Korinek V. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-cantenin or APC.  Science 1997:275:1787–1790.

Journal article published online ahead of print:

Farrall AL, Riemer P, Leushacke M, et al. Wnt and BMP signals control intestinal adenoma cell fates. Int J Cancer 2012;[Epub ahead of print]. doi:10.1002/ijc.27500.

Website citation:

Authors last name followed by first and middle initials.  Use commas only between names; no other punctuation in author names. If more than 3 authors use et al.  Full title of webpage. Website address. Page number (if available).  Last accessed date.

Benard C, Cultrone A, Michel C, et al. Degraded carrageenan causing colitis in rats induces TNF secretion and ICAM-1 upregulation in monocytes through NF-kappaB activation., 2010;5:e8666.

Book chapter from an edited book:

Authors of chapter. Title of chapter. In: Name of book.  Editor(s); inclusive page range of chapter. Location of publisher: Name of publisher; year.

Gregus Z, Klaasssen CD. Mechanisms of toxicity.  In: Cassarett & Doul’s toxicology:  the basic science of poisons 6th ed.  CD Klaassen (ed); pp. 68-69. New York: McGraw Hill; 2001.

Conference Proceedings:

Please follow this structure for Conference Proceeding references, including capitalization and punctuation:

List all Authors’ (or) Editors’ names (last name first, followed by first and middle initials).  Conference title. Date of conference. Location of conference. City of publisher: Publisher; Year of publication. Complete number of pages in proceedings book.

Citation for a published report:

JECFA: Joint FAO/WHO expert committee on food additives.   68th meeting of the joint FAO/WHO expert committee on food additives: safety evaluation of certain food additives and contaminants, held on 19–28 June 2007 in Geneva, Switzerland, WHO food additives series: 2008;59, p. 65–85.

Unpublished Material
When a reference is unpublished data, a manuscript in preparation, or a manuscript submitted but not in press, it should be included in parentheses in the body of the text, and not cited in the reference list. Personal communications should also be listed parenthetically in text, and should contain the first initial and last name of the contact, as well as the month and year of the communication. Published manuscripts, and those that have been accepted and are pending publication, should be cited in the reference list.



Submit table(s), each with its own title, as a separate file from the text of the manuscript. Use Arabic numerals to number tables. Table legends and/or footnotes should be double-spaced.


Prepare a separate list of figure legends, double-spaced, and upload in a separate file.

Please follow these guidelines for submitting figures.

  • Do NOT embed art files into a Word or PDF document.
  • Line illustrations should be submitted at a minimum of 900 dpi.
  • Halftones and color should be submitted at a minimum of 300 dpi.
  • Black and White art must be submitted as grayscale—not RGB.
  • Save as either TIFF or EPS files.
  • Color art must be saved as CYMK—not RGB.
  • PowerPoint and Excel files cannot be accepted

  • Name figure files using only alphanumeric characters.  Do not use symbols, dots, or dashes.
  • File names should be formatted with first author’s last name and the figure number. (Ex:  SmithFig1)



The cost of printing figures in color must be subsidized by the author(s). Cost estimates are available from the Publisher upon request.



Patients and Study Participants


All manuscripts must comply with the privacy and confidentiality requirements outlined on the Uniform Requirements for Manuscripts Submitted to Biomedical Journals website. For more information, visit    

When articles include reports of studies on human subjects, state in the Methods section that an appropriate institutional review board or ethics committee approved the study. Authors who do not have formal ethics review committees should follow the principles of the Declaration of Helsinki. In the Methods section, state that informed consent was obtained from subjects (specify written or verbal).


The principal author must state that if animals were used experimentally, permission was obtained from the appropriate committee(s), and that the animals were treated humanely and the standards conformed to those of current ethical animal research practices.


In addition, text and photographs should not reveal any identifying information unless it is essential for scientific purposes (in which case, consent should be obtained). Masking the subjects’ eyes in photographs is often insufficient to protect their identity.




Study Design and Ethics

Documented review and approval from a formally constituted review board (Institutional Review Board or Ethics committee) should be required for all studies involving people, medical records, and human tissues. For those investigators who do not have access to formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. If the study is judged exempt from review, a statement from the committee should be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and a sentence declaring adherence should be included in the acknowledgment section of the manuscript.

Animal experiments should require full compliance with local, national, ethical, and regulatory principles, and local licensing arrangements.

Definitions of Scientific Misconduct

Mary Ann Liebert, Inc., publishers generally follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

  • Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
  •  Authorship Disputes: Deliberate misrepresentation of a scientist’s contribution to the published work, or purposefully omitting the contributions of a scientist.

  • Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.

  • Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.

  • Material failure to comply with legislative and regulatory requirements affecting research:
    Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.

  • Conflict of Interest:  Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
  • Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
  • Plagiarism: Purposely claiming another’s work or idea as your own constitutes misconduct and/or fraud.

  • Simultaneous Submission:  Submitting a paper to more than one publication at the same time constitutes misconduct.

Responding to Allegations of Possible Misconduct

The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation.  As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.

When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper.  In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.

If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record.  If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.

All allegations will be kept confidential.



Upon acceptance of any manuscript, all authors will receive a follow-up email with instructions on how to complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors’ email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications.

The corresponding author is responsible for communicating with coauthors to ensure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright.

If a co-author does not receive the email notification with the unique link to direct access, the pending copyright form may be completed by logging on to the Manuscript Central system using the author’s credentials.  Click on Author Center and complete the forms located under “Manuscripts I Have Coauthored,” or “Manuscripts with Decisions” if you are listed as the corresponding author on the paper.


Failure by all authors to submit this form will result in a delay in publication.




Patients and Study Participants

Applied In Vitro Toxicology follows the guidelines set forth by the International Committee for Medical Journal Editors. All submissions must comply with the privacy, confidentiality, and ethics requirements outlined in the ICMJE Recommendations ("The Uniform Requirements").  Visit:  


When articles include reports of studies on human subjects, state in the Methods section that an appropriate institutional review board or ethics committee approved the study. Authors who do not have formal ethics review committees should follow the principles of the Declaration of Helsinki (revised 2013). In the Methods section, state that informed consent was obtained from subjects (specify written or verbal).


In addition, text and photographs should not reveal any identifying information unless it is essential for scientific purposes (in which case, consent should be obtained). Masking the subjects’ eyes in photographs is often insufficient to protect their identity.


Animal Studies

The principal author must state that if animals were used experimentally, permission was obtained from the appropriate committee(s), and that the animals were treated humanely and the standards conformed to those of current ethical animal research practices.


The Publisher is not responsible for the publication of any identifiable information in a manuscript or any of its accompanying material.


Figures, tables, and text taken from other sources must be accompanied by a written statement from both author and publisher, granting permission for reproduction Include written permission from authors to cite unpublished data or papers still in press.


Once a paper is accepted for publication, changes in authorship in the page proof stage are NOT permitted under any circumstance.

Page proofs will be sent to the (one) corresponding author as designated when the manuscript was uploaded to Manuscript Central. It is the corresponding author’s responsibility to share the page proofs with co-authors and to coordinate all authors’ corrections into one proof. The Publisher will not accept corrections from multiple authors.


Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.


Applied In Vitro Toxicology is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801. Tel: 914-740-2100; Fax: 914-740-2108; Email:; Website:

Our dynamic Author Benefits Program provides you with end-to-end benefits that ensure your hard work pays off and your published manuscript gets the attention it deserves not just upon publication, but permanently.

Liebert Open Access

Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option

Explore Liebert Open Access

Does your research funder have an open access mandate or would you like to expand the dissemination of your research?

The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.

The benefits of Liebert Open Access include:

  • High visibility; open access articles are freely available online upon publication
  • You retain copyright with the open access license allowing broad dissemination of your research
  • You can freely share your article in repositories and research networks without restrictions
  • Easy compliance with open access mandates
  • Rigorous editorial and peer-review
  • Targeted email announcement featuring a direct link to article

Identification and Marketing

Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.

Copyright and Licensing

If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

At this time we allow authors to choose between the CC-BY or CC-BY-NonCommercial license. A limited number of journals offer NonCommercial licenses exclusively.

Ordering Open Access

Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email

Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form.  You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.

Publishing biomedical or biotechnology research?

Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.

 *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.


Browse journals in the Liebert Open Access portfolio:

NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

Publishing in Subscription Journals

By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.

Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.

The final published article (version of record) can never be archived in a repository, preprint server, or research network.


Publishing Open Access

Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email or visit Liebert Open Access for more information.

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Society Affiliation

The Official Journal of: